Protection from renal ischemia reperfusion injury by an endothelin-A receptor antagonist BQ-123 in relation to nitric oxide production

Toxicology

Volumn 228, Issue 2-3, 2006, Pages 219-228

  Erdogan, Hasan ^a   Fadillioglu, Ersin ^b   Emre, Memet Hanifi ^c  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c INONU UNIVERSITY   (Turkey)

Author keywords

Endothelin 1; Endothelin A receptor antagonist; Nitric oxide; Renal ischemia reperfusion

Indexed keywords

ARGININE; CATALASE; CREATININE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR ANTAGONIST; GLUTATHIONE PEROXIDASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; SODIUM; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; KIDNEY ISCHEMIA; KIDNEY PERFUSION; LIPID PEROXIDATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BLOOD PRESSURE; BLOOD UREA NITROGEN; CATALASE; ENDOTHELIN-1; ENZYME INHIBITORS; GLUTATHIONE PEROXIDASE; KIDNEY; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ORGAN SIZE; PEPTIDES, CYCLIC; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RENAL CIRCULATION; REPERFUSION INJURY; SODIUM; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; XANTHINE OXIDASE;

EID: 33750735109     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2006.08.039     Document Type: Article

References (49)

1. Aebi H. Catalase. In: Bergmeyer H.U. (Ed). Methods of Enzymatic Analysis (1974), Academic Press, New York and London pp. 673-677
2. Arai H., Hori S., Aramori I., Ohkubo H., and Nakanishi S. Cloning and expression of cDNA encoding an endothelin receptor. Nature 348 (1990) 730-732
3. Bachmann S., and Mundel P. Nitric oxide in the kidney: synthesis, localization, and function. Am. J. Kidney Dis. 24 (1994) 112-129
4. Battistini B., and Dussault P. The many aspects of endothelins in ischemia-reperfusion injury: emergence of a key mediator. J. Invest. Surg. 11 (1998) 297-313
5. Brooks D.P., dePalma P.D., Gellai M., Nambi P., Ohlstein E.H., Elliott J.D., Gleason J.G., and Ruffolo Jr. R.R. Nonpeptide endothelin receptor antagonists. Part III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs. J. Pharmacol. Exp. Ther. 271 (1994) 769-775
6. Buyukgebiz O., Aktan A.O., Haklar G., Yalcin A.S., Yegen C., Yalin R., and Ercan Z.S. BQ-123, a specific endothelin (ETA) receptor antagonist prevents ischemia-reperfusion injury in kidney transplantation. Transpl. Int. 9 (1996) 201-207
7. Cortas N.K., and Wakid N.W. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin. Chem. 36 (1990) 1440-1443
8. Dagher F., Polling R.M., Rogers D.M., Gennaro M., and Ascer E. The value and limitations of l-Arg infusion on glomerular and tubular function in the ischemic/reperfused kidney. J. Vasc. Surg. 21 (1995) 453-459
9. De Nucci G., Gryglewski R.J., Warner T.D., and Vane J.R. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells coupled. Proc. Natl. Acad. Sci. U.S.A. 85 (1998) 2334-2338
10. Dobashi K., Ghosh B., Orak J.K., Singh I., and Singh A.K. Kidney ischemia-reperfusion: modulation of antioxidant defenses. Mol. Cell. Biochem. 205 (2000) 1-11
11. Douglas S.A., Gellai M., Ezekiel M., and Ohlstein E.H. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J. Hypertens. 12 (1994) 561-567
12. Esterbauer H., and Cheeseman K.H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. In: Packer L., and Glazer A.N. (Eds). Methods in Enzymology, vol. 186, Oxygen Radicals in Biological Systems (1990), Academic Press, California 407-421
13. Gellai M., Jugus M., Fletcher T., DeWolf R., and Nambi P. Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat. J. Clin. Invest. 93 (1994) 900-906
14. Goto K. Pulmonary Actions of Endothelins-History of Endothelin (1999), Birkhauser Verlag Basel, Switzerland pp. 1-20
15. Gourine A.V., Gonon A.T., and Pernow J. Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am. J. Physiol.: Heart Circ. Physiol. 280 (2001) H1105-H1112
16. Hellberg P.O., Kallskog O.T., Ojteg G., and Wolgast M. Peritubular capillary permeability and intravascular RBC aggregation after ischemia: effects of neutrophils. Am. J. Physiol. 258 (1990) F1018-F1025
17. Honing M.L.H., Hijmering M.L., Ballard D.E., Yang Y.P., Padley R.J., Morrison P.J., and Rabelink T.J. Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J. Am. Soc. Nephrol. II (2000) 1498-1504
18. Hoy A., Leininger-Muller B., Kutter D., Siest G., and Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin. Chem. Lab. Med. 40 (2002) 2-8
19. Hughes A.K., Stricklett P.K., Padilla E., and Kohan D.E. Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int. 49 (1996) 181-189
20. Hunley T.E., and Kon V. Update on endothelins biology and clinical implications. Pediatr. Nephrol. 16 (2001) 752-762
21. Irmak M.K., Koltuksuz U., Kutlu N.O., Yagmurca M., Ozyurt H., Karaman A., and Akyol O. The effect of caffeic acid phenethyl ester on ischemia-reperfusion injury in comparison with alpha-tocopherol in rat kidneys. Urol. Res. 29 (2001) 190-193
22. Kelly K.J., Williams Jr. W.W., Colvin R.B., and Bonventre J.V. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 812-816
23. Knoll T., Schult S., Birck R., Braun C., Michel M.S., Bross S., Juenemann K.P., Kirchengast M., and Rohmeiss P. Therapeutic administration of an endothelin-A receptor antagonist after acute ischemic renal failure dose-dependently improves recovery of renal function. J. Cardiovasc. Pharmacol. 37 (2001) 483-488
24. Krishan P., Sharma A., and Singh M. Effect of angiotensin converting enzyme inhibitors on ischaemia-reperfusion-induced renal injury in rats. Pharmacol. Res. 37 (1998) 23-29
25. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W., Shaltiel S., and Stantman E.R. In: Packer L., and Glazer N.A. (Eds). Determination of Carbonyl Content in Oxidatively Modified Proteins. Meth. Enzymol. (Calif.) 186 (1990) 464-479
26. Lowry O., Rosenbraugh N., Farr L., and Rondall R. Protein measurement with the Folin-phenol reagent. J. Biol. Chem. 183 (1951) 265-275
27. Luscher T.F., and Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102 (2000) 2434-2440
28. In: Metcalf J.A., Galin J.I., Nauseef W.M., and Roo R.K. (Eds). Laboratory Manual of Neutrophil Function (1986), Raven Press, New York pp. 150-153
29. Ozdemir R., Parlakpinar H., Polat A., Colak C., Ermis N., and Acet A. Selective endothelin A (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology 219 (2006) 142-149
30. Paglia D.E., and Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70 (1967) 158-170
31. Prajda N., and Weber G. Malign transformation-linked imbalance: decreased XO activity in hepatomas. FEBS Lett. 59 (1975) 245-249
32. Ray A., Hegde L.G., Chugh A., and Gupta B. Endothelin-receptor antagonists: current and future perspectives. Drug Discov. Today 5 (2000) 455-464
33. Rubanyi G.M., and Polokof M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46 (1994) 325-415
34. Ruschitzka F., Shaw S., Gygi D., Noll G., Barton M., and Luscher T.F. Endothelial dysfunction in acute renal failure: role of circulating and tissue endothelin-1. J. Am. Soc. Nephrol. 10 (1999) 953-962
35. Saito M., and Miyagawa I. Real-time monitoring of nitric oxide in ischemia-reperfusion rat kidney. Urol. Res. 28 (2000) 141-146
36. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., and Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348 (1990) 732-735
37. Schmidt A., Bayerle-Eder M., Pleiner H., Zeisner C., Wolzt M., Mayer G., and Schmetterer L. The renal and systemic hemodynamic effects of a nitric oxide-synthase inhibitor are reversed by a selective endothelin(A) receptor antagonist in men. Nitric Oxide 5 (2001) 370-376
38. Schramm L., Heidbreder E., Lopau K., Schaar J., De Cicco D., Gotz R., and Heidland A. Toxic acute renal failure in the rat: effect of l-arginine and N-methyl-l-arginine on renal function. Nephrol. Dial. Transpl. 9 (1994) 88-93
39. Stoos B.A., Garcia N.H., and Garvin J.L. Nitric oxide inhibits sodium reabsorption in the isolated perfused cortical collecting duct. J. Am. Soc. Nephrol. 6 (1995) 89-94
40. Sun Y., Oberley L.W., and Li Y. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 34 (1988) 497-500
41. Suresh D.P., Lamba S., and Abraham W.T. New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists. J. Card. Fail. 6 (2000) 359-368
42. Tome L.A., Yu L., de Castro I., Campos S.B., and Seguro A.C. Beneficial and harmful effects of l-arginine on renal ischaemia. Nephrol. Dial. Transpl. 14 (1999) 1139-1145
43. Valdivielso J.M., Crespo C., Alonso J.R., Martinez-Salgado C., Eleno N., Arevalo M., Perez-Barriocanal F., and Lopez-Novoa J.M. Renal ischemia in the rat stimulates glomerular nitric oxide synthesis. Am. J. Physiol.: Regul. Integr. Comp. Physiol. 280 (2001) R771-R779
44. Waz W.R., Van Liew J.B., and Feld L.G. Nitric oxide metabolism following unilateral renal ischemia/reperfusion injury in rats. Pediatr. Nephrol. 12 (1998) 26-29
45. Webb M.L., and Meek T.D. Inhibitors of endothelin. Med. Res. Rev. 17 (1997) 17-67
46. Wilhelm S.M., Stowe N.T., Robinson A.V., and Schulak J.A. The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function. Transplantation 27 71 (2001) 211-216
47. Winterbourn C.C., and Kettle A.J. Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic. Biol. Med. 29 (2000) 403-409
48. + exchange inhibitor, KB-R7943, shows renal protective effects in rats with ischemic acute renal failure. J. Pharmacol. 296 (2001) 412-419
49. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415